PMID- 14720331
OWN - NLM
STAT- MEDLINE
DCOM- 20040428
LR  - 20201215
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 95
IP  - 1
DP  - 2004 Jan
TI  - Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with 
      metastatic hormone-refractory prostate cancer.
PG  - 77-84
AB  - To evaluate the safety and toxicity of peptide vaccination for patients with 
      metastatic hormone-refractory prostate cancer (HRPC) based on pre-existing 
      peptide-specific cytotoxic T-lymphocyte (CTL) precursors in the circulation, 10 
      patients positive for human leukocyte antigen (HLA)-A2 with metastatic HRPC were 
      enrolled in a phase I study. Peptide-specific CTL-precursors reactive to 16 kinds 
      of vaccine candidates in the pre-vaccination peripheral blood mononuclear cells 
      (PBMCs) were measured, and patients were followed by vaccination with only 
      positive peptides (up to 4 kinds of peptides). Serum prostate-specific antigen 
      (PSA) levels were monitored regularly. The peptide vaccination was safe and well 
      tolerated with no major adverse effects. The most common toxicities were 
      dermatologic reactions at the injection site. Increased CTL response to peptides 
      was observed in 4 of 10 patients. Anti-peptide IgG was also detected in 
      post-vaccination sera of 7 of 10 patients. One patient showed the disappearance 
      of a pelvic bone metastasis after five vaccinations. Three patients showed a 
      decrease of serum PSA level from the baseline after the vaccination, but no 
      patients showed a serum PSA level decrease of >/= 50%. The median survival 
      duration of study patients was 22 months with follow-up from 3 to 27 months. We 
      consider that the increase in cellular and humoral immune responses, and decrease 
      in PSA level in some patients justify further development of peptide vaccination 
      for metastatic HRPC patients.
FAU - Noguchi, Masanori
AU  - Noguchi M
AD  - Department of Urology, Kurume University School of Medicine, ururume 830-0011, 
      Japan. noguchi@med.kurume-u.ac.jp
FAU - Itoh, Kyogo
AU  - Itoh K
FAU - Suekane, Shigetaka
AU  - Suekane S
FAU - Yao, Akihisa
AU  - Yao A
FAU - Suetsugu, Norie
AU  - Suetsugu N
FAU - Katagiri, Kazuko
AU  - Katagiri K
FAU - Yamada, Akira
AU  - Yamada A
FAU - Yamana, Hideaki
AU  - Yamana H
FAU - Noda, Shinshi
AU  - Noda S
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase I
PT  - Journal Article
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Vaccines, Subunit)
RN  - 33515-09-2 (Gonadotropin-Releasing Hormone)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Adenocarcinoma/immunology/pathology/*therapy
MH  - Aged
MH  - Cancer Vaccines/adverse effects/*therapeutic use
MH  - Drug Resistance, Neoplasm
MH  - Gonadotropin-Releasing Hormone/therapeutic use
MH  - HLA-A2 Antigen/*immunology
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - Male
MH  - Middle Aged
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Neoplasms/immunology/pathology/*therapy
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Vaccines, Subunit/adverse effects/*immunology/therapeutic use
EDAT- 2004/01/15 05:00
MHDA- 2004/04/29 05:00
CRDT- 2004/01/15 05:00
PHST- 2004/01/15 05:00 [pubmed]
PHST- 2004/04/29 05:00 [medline]
PHST- 2004/01/15 05:00 [entrez]
AID - 10.1111/j.1349-7006.2004.tb03174.x [doi]
PST - ppublish
SO  - Cancer Sci. 2004 Jan;95(1):77-84. doi: 10.1111/j.1349-7006.2004.tb03174.x.